Top

Published in:

01-08-2016 | Original Article

Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy

Authors: Taito Masawa, Shichiro Abe, Shigeru Toyoda, Masashi Sakuma, Takahisa Nasuno, Michiya Kageyama, Michiaki Tokura, Satoshi Koizumi, Isao Taguchi, Teruo Inoue

Published in: Heart and Vessels | Issue 8/2016

Abstract

Overall stent performance should be characterized by geometric luminal gain acquisition, neointimal coverage of the stent struts, and stabilization of the underlying inflammatory neoatheroma. The aim of this study was to compare the performance of zotarolimus-eluting stent (ZES), everolimus-eluting stent (EES) and bare metal stent (BMS) using optical coherence tomography (OCT) and coronary angioscopy. For 36 stented coronary lesions (BMS, 12 lesions; ZES, 11 lesions; EES, 13 lesions) in 27 patients, we calculated neointimal area and uncovered stent strut rate based on OCT findings at 10 months after stent placement. The grades of neointimal coverage and yellow color, both of which were classified from 0 to 3, were also assessed by coronary angioscopy. The plaque area of the ZES lesions was larger than that of the EES lesions (P < 0.05) but smaller than that of the BMS lesions (P < 0.05). The OCT-based uncovered rate of the ZES lesions was less than that of the EES lesions (P < 0.01), but similar to that of the BMS lesions. The stent coverage grade by angioscopy was higher in the ZES lesions than in the EES lesions (P < 0.05), but similar to the BMS lesions. The yellow grade was less in the ZES lesions than in the EES lesions (P < 0.01), but similar to the BMS lesions. ZES might be better than BMS in terms of neointimal thickening, and better than EES in terms of neointimal coverage as well as prevention of neoatheroma formation. ZES may have superior performance compared with EES.

Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR (1996) Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1998:2277–2283CrossRef

Costa M, Simon D (2005) Molecular basis of restenosis and drug-eluting stents. Circulation 111:2257–2273CrossRefPubMed

Inoue T, Node K (2009) Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 73:615–621CrossRefPubMed

Rogers C, Parikh S, Scifert P, Edelman E (1996) Endogenous cell seeding: remnant endothelium after stenting enhances vascular repair. Circulation 94:2909–2914CrossRefPubMed

Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI (2011) Vascular inflammation and repair: implication for reendothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4(10):1057–1066CrossRefPubMedPubMedCentral

Farb A, Burke AP, Kolodgie FD, Virmani R (2003) Pathological mechanisms of fetal late coronary stent thrombosis in humans. Circulation 108:1701–1706CrossRefPubMed

Alfonso F, Suárez A, Pérez-Vizcayno MJ, Moreno R, Escaned J, Bañuelos C, Jiménez P, Bernardo E, Angiolillo DJ, Hernández R, Macaya C (2007) Inravascular ultraaound findings during episodes of drug-eluting stent thrombosis. J Am Coll Cardiol 50:2095–2097CrossRefPubMed

Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S (2007) Incomplete stent apposition and very late stent thrombosis after drug-eluting stent inplantation. Circulation 115:2426–2434CrossRefPubMed

Taguchi I, Yoneda S, Abe S, Toyoda S, Nasuno T, Nishino S, Kageyama M, Tokura M, Ogawa M, Node K, Inoue T (2014) The late phase inflammatory response after drug-eluting stent implantation. Heart Vessels 29:213–219CrossRefPubMed

10.

Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R (2011) The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 57:1314–1322CrossRefPubMedPubMedCentral

11.

Akazawa Y, Matsuo K, Ueda Y, Nishio M, Hirata A, Asai M, Nemoto T, Wada M, Murakami A, Kashiwase K, Kodama K (2014) Atherosclerotic change at one year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent. Circ J 78:1428–1436CrossRefPubMed

12.

Nasuno T, Kageyama M, Toyoda S, Sakuma M, Komatsu T, Taguchi I, Abe S, Inoue T (2015) The wound healing response after implantation of a drug-eluting stent is impaired persistently in the long-term. Heart Vessels. doi:10.1007/s00380-015-0676-y PubMedCentral

13.

Haase J, Escand J, van Swijndregt EM, Ozaki Y, Gronenschild E, Slager CJ, Serruys PW (1993) Experimental validation of geometrical and densitometric measurements on the new generation coronary angiography analysis system (CAAS II). Cathet Cariovasc Diagn 30:104–114CrossRef

14.

Mastumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada T, Paredes OL, Hirata K, Yokoyama M (2007) Neointimal coverage of sirolimus-eluting stents at 6 months follow-up: evaluated by optical coherence tomography. Eur Heart J 28:961–967CrossRef

15.

Ishigami K, Uemura S, Morikawa Y, Soeda T, Okayama S, Nishida T, Takemoto Y, Onoue K, Somekawa S, Takeda Y, Kawata H, Horii M, Saito Y (2009) Long term follow-up of neointimal coverage of sirolimus-eluting stent: evaluation with optical coherence tomography. Circ J 73:2300–2307CrossRefPubMed

16.

Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, Mintz GS, Nagata S (2006) Incomplete neointimal coverage of sirolimus-eluting stents. J Am Coll Cardiol 47:2108–2111CrossRefPubMed

17.

Awata M, Kotani J, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Nanto S, Hori M, Nagata S (2007) Serial angioscopic evidence of neointimal coverage after sirolimus-eluting stents implantation: comparison with bare-metal stents. Circulation 116:910–916CrossRefPubMed

18.

Awata M, Nanto S, Uematsu M, Morozumi T, Watanabe T, Onishi T, Iida O, Sera F, Minamiguchi H, Kotani J, Nagata S (2009) Heterogeneous arterial healing in patients following paclitaxel-eluting stent implantation. JACC Cardiovasc Interv 2:453–458CrossRefPubMed

19.

Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB (2011) Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents: 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv 4:543–550CrossRefPubMed

20.

Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O’Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas John S, Jr JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM III, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE, ENDEAVOR IV Investigators (2010) A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 55:543–554CrossRefPubMed

21.

Gada H, Kirtane AJ, Newman W, Sanz M, Hermiller JB, Mahaffey KW, Cutlip DE, Sudhir K, Hou L, Koo K, Stone GW (2013) 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III Trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions). JACC Cardiovasc Interv 6:1263–1266CrossRefPubMed

22.

Chen KY, Rha SW, Wang L, Li YJ, Li GP, Poddar KL, Park JY, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim CJ, Yoon JH, Chung WS, Seung KB, Park SJ, KAMIR Investigators (2012) Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction a propensity score-matched analysis. JACC Cardiovasc Interv 5:936–945CrossRefPubMed

23.

Omar A, Torguson R, Kitabata H, Pendyala LK, Loh JP, Magalhaes MA, Satler LF, Suddath WO, Pichard AD, Waksman R (2014) Long-term safety and efficacy of second-generation everolimus-eluting stent compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome. Catheter Cardiovasc Interv 84:1053–1060CrossRefPubMed

24.

Miyamoto A, Prieto AR, Friedl SE, Lin FC, Muller JE, Nesto RW, Abela GS 2nd (2004) Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy: implications for identifying the vulnerable plaque. Clin Cardiol 27:9–15CrossRefPubMed

25.

Ishibashi F, Lisauskas JB, Kawamura A, Waxman S (2008) Topographic association of angioscopic yellow plaques with coronary atherosclerotic plaque: assessment with quantitative colorimetry in human coronary artery autopsy specimen. Int J Cardiovasc Imaging 24:1–5CrossRefPubMed

26.

Ueda Y (2014) Intracoronary imaging of in-stent atherosclerosis by coronary angioscopy and optical coherence tomography. Circ J 76:61–62CrossRef

27.

Ta Taniwaki M, Stefanini GG, Silber S, Richard G, Vranckx P, Serruys PW, Buszman PE, Kelback H, Windecker S (2014) 4-year clinical outcome and predictors of repeat revascularization in patients treated with new generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol 63:1617–1625CrossRef

28.

Gutiérrez-Chico JL, van Geuns RJ, Regar E, van der Giessen WJ, Kelbæk H, Saunamäki K, Escaned J, Gonzalo N, di Mario C, Borgia F, Nüesch E, García-García HM, Silber S, Windecker S, Serruys PW (2011) Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial. Eur Heart J 32:2454–2463CrossRefPubMedPubMedCentral

29.

Kim JS, Kim BK, Jang IK, Shin DH, Ko YG, Choi D, Hong MK, Cho YK, Nam CW, Hur SH, Choi JH, Song YB, Hahn JY, Choi SH, Gwon HC, Jang Y (2012) ComparisOn of neointimal coVerage betwEen zotaRolimus-eluting stent and everolimus-eluting stent using Optical Coherence Tomography (COVER OCT). Am Heart J 163:601–607CrossRefPubMed

30.

Yoneda S, Abe S, Taguchi I, Masawa N, Inoue K, Inoue T (2012) Inflammation and impaired wound healing after zotarolimus-eluting stent implantation. Cardiovasc Pathol 21:511–514CrossRefPubMed

Title: Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy
Authors: Taito Masawa
Shichiro Abe
Shigeru Toyoda
Masashi Sakuma
Takahisa Nasuno
Michiya Kageyama
Michiaki Tokura
Satoshi Koizumi
Isao Taguchi
Teruo Inoue
Publication date: 01-08-2016
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 8/2016
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-015-0728-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Comparison of the performance of zotarolimus- and everolimus-eluting stents by optical coherence tomography and coronary angioscopy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2016

Prevalence, implication, and determinants of worsening renal function after surgery for congenital heart disease

Aberrant serum polyunsaturated fatty acids profile is relevant with acute coronary syndrome

Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Antiplatelet therapy in Takotsubo cardiomyopathy: does it improve cardiovascular outcomes during index event?

Comparison of magnetic wire navigation with the conventional wire technique for percutaneous coronary intervention of chronic total occlusions: a randomised, controlled study

Percutaneous retrieval of a radiolucent anchoring sleeve embolized in pulmonary artery during pacemaker implantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page